Cargando…
Drug Therapy for Obstructive Sleep Apnea: Are We There Yet?
Autores principales: | Schmickl, Christopher N., Edwards, Bradley A., Malhotra, Atul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875900/ https://www.ncbi.nlm.nih.gov/pubmed/35320066 http://dx.doi.org/10.1164/rccm.202202-0301ED |
Ejemplares similares
-
Telemedicine for enhancing positive airway pressure compliance in obstructive sleep apnea: Are we on cloud nine yet?
por: Suri, Tejas M., et al.
Publicado: (2023) -
Pathogenesis of obstructive sleep apnea in individuals with the COPD + OSA Overlap syndrome versus OSA alone
por: Orr, Jeremy E., et al.
Publicado: (2020) -
Are we underestimating the lifelong benefits of therapy for obstructive sleep apnea?
por: Berman, Alec M, et al.
Publicado: (2016) -
Effects of acetazolamide on control of breathing in sleep apnea patients: Mechanistic insights using meta‐analyses and physiological model simulations
por: Schmickl, Christopher N., et al.
Publicado: (2021) -
Point-of-care prediction model of loop gain in patients with obstructive sleep apnea: development and validation
por: Schmickl, Christopher N., et al.
Publicado: (2022)